<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124469">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02024373</url>
  </required_header>
  <id_info>
    <org_study_id>CSDH2013</org_study_id>
    <nct_id>NCT02024373</nct_id>
  </id_info>
  <brief_title>Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma</brief_title>
  <official_title>Multi-Center, Randomized, Placebo-Controlled, Double Blind Study of the Atorvastatin: Effect on Patients With Chronic Subdural Hematoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oriental Neurosurgery Evidence-Based-Study Team</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oriental Neurosurgery Evidence-Based-Study Team</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinic effects and security of oral administration of Atorvastatin on
      chronic subdural hematoma (CSDH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      Multi-center, randomized, double-blind, placebo parallel controlled

      Subjects:

      Patients with chronic subdural hematoma (CSDH)

      Sample size:

      200, including an Atorvastatin-treated group of 100 patients and a control group of 100
      subjects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hematoma Reduced Amount.</measure>
    <time_frame>Check on  8 weeks during treatment (at the end)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary efficacy endpoint: hematoma reduced amount. Outcome Measures: all patients underwent head CT (plain scan) before treatment, and check on 8 weeks during treatment (at the end)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The consciousness score (MGS-GCS) and outcome score (GOS, ADL-BI Scale) in subjects</measure>
    <time_frame>0，7days，4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of neurological symptoms and signs</measure>
    <time_frame>0，7days，4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of routine blood test and coagulation results</measure>
    <time_frame>0，7days，4, 8weeks during treatment (at the end), in the follow-up in 3 and 6 months.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Subdural Hematoma</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atorvastatin：20 mg (every evening orally) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo:20 mg (every evening orally) for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>20 mg (every evening orally) for 8 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>20 mg (every evening orally) for 8 weeks</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≧ 18 and ≤90 years old, male or female;

          2. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma
             (MRI scan is warranted if diagnosis is difficult);

          3. Markwalder's Grading Scale and Glasgow Coma Scale (MGS-GCS)＜Grade 3;

          4. Attending physician makes a judgment that cerebral hernia would not occur and
             surgical operation might not be performed in a short time. Conservative treatment is
             adopted;

          5. Patients have never undergo surgery on the hematoma

          6. Patient fully understood the nature of the study, and voluntarily participates and
             signs informed consent.

        Exclusion Criteria:

          1. Allergic to the statin or its ingredients

          2. Cerebral herniation might occur at any time;

          3. Hematoma leads to herniation and warrants surgical operation.

          4. Hematoma caused by tumors, blood and other known comorbidities;

          5. Abnormal liver function

          6. Uncontrolled hepatitis and other liver diseases, as well as suffering from other
             disease may interfere the study

          7. Patients have been on oral Statin treatment for a long time.

          8. Patients have been on oral Steroids treatment for a long time.

          9. In the past a year, patients have been on anti-platelet or warfarin

         10. Participate in clinical trials in the past four weeks;

         11. Pregnant or breastfeeding

         12. Failure of completing the trial by poor compliance;

         13. For any reason, the researchers believe that the case is not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ning jian zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tianjin Medical University General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RongCai Jiang, MD, PhD</last_name>
    <phone>86-22-60814348</phone>
    <email>jianghope@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing tiantan hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rongcai Jiang, MD, PhD</last_name>
      <phone>86-22-60814348</phone>
      <email>jianghope@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jianning Zhang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking union medical college hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xiangya hospital central southe university</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southwest hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>West china hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Haerbing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The second Affiliated hospital of zhejiang university school of medicine</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Qilu hospital of shandong university</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huashan hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Xianggang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 25, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>chronic subdural hematoma</keyword>
  <keyword>Atorvastatin</keyword>
  <keyword>oral administration therapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Hematoma, Subdural, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
